6 Analysts reported that the Price Target for Aurinia Pharmaceuticals Inc. might touch $10 high while the Average Price Target and Low price Target is $8.42 and $7 respectively. Aurinia Pharmaceuticals Inc. got Initiated on 30-Jun-16 where investment firm H.C. Wainwright Initiated the stock to Buy.
Several investment firms issued their expert ratings on Aurinia Pharmaceuticals Inc. Finally, Canaccord Genuity reissued a "buy" rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Saturday, October 8th.
The stock recently closed its previous session at $3.22 by showing a percentage change of 5.57% from its previous day closing price of $3.05.
Analyst Rating on Aurinia Pharmaceuticals Inc.
EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -53.40%, and looking further price to next year's EPS is 57%. Leerink Swann Initiates Coverage on the stock to Outperform on 2/02/15 by stationing a price target of $8. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. Aurinia Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $5.69. The difference between Actual EPS and Estimated EPS was -0.07 Percent. (NASDAQ:AUPH) could bring EPS of $-0.14/share. The company has a 1 Year high price target of $8.42. The stock traded with the volume of 7 Million shares in the last trading session. The Company showed a negative -22.50% in the net profit margin. In the past week, the company has outperformed the S&P 500 by 25.98% and the outperformance has advanced to 49.6% for the last 4 weeks period.The stock has recorded a 20-day Moving Average of 33.09% and the 50-Day Moving Average is 17.03%.The 200 Day SMA reached 13.19%. Taking a look into the performance of AUPH stock, investor will come to know that the weekly performance for this stock is valued at 27.27%, resulting in a performance for the month at 50.47%.
Beta factor of the stock stands at 0.54. (NASDAQ:SRPT) also listed in significant eye catching mover, SRPT attains returns on investment ratio of -103%, which suggests it's viable on security that has lesser ROI.
While looking at the Stock's Performance, Aurinia Pharmaceuticals Inc. now shows a Weekly Performance of 27.27%, where Monthly Performance is 50.47%, Quarterly performance is -3.59%, 6 Months performance is 5.57% and yearly performance percentage is 54.07%.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity.
The Relative Volume of the company is 4.44 and Average Volume (3 months) is 1.57 million. On annual basis, the FY2016 Estimate trend at current was $-0.70 as compared to three months ago was $-0.70, according to WSJ analytic reports. AUPH has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0 and Price to Free Cash Flow (P/FCF) value of 0.